Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | S100A4 | P26447 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435695 | 0.89 | S100A4 (0.44) | PDK1S100A4TRPV1CYP1A2KDM4E | |
| SCHEMBL2953964 | 0.85 | ACHE (0.43) | PDK1S100A4TRPV1CYP1A2KDM4E | |
| SCHEMBL29561732 | 0.85 | S100A4 (0.46) | PDK1S100A4TRPV1CYP1A2KDM4E | |
| SCHEMBL1199050 | 0.85 | S100A4 (0.46) | PDK1S100A4TRPV1CYP1A2KDM4E | |
| SCHEMBL14756219 | 0.83 | TSHR (0.56) | PDK1S100A4TRPV1CYP1A2KDM4E | |
| SCHEMBL961045 | 0.83 | S100A4 (0.45) | PDK1S100A4TRPV1CYP1A2KDM4E | |
| SCHEMBL29291499 | 0.83 | S100A4 (0.45) | PDK1S100A4TRPV1CYP1A2KDM4E | |
| SCHEMBL31272132 | 0.83 | S100A4 (0.45) | PDK1S100A4TRPV1CYP1A2KDM4E | |
| SCHEMBL3526369 | 0.83 | S100A4 (0.45) | PDK1S100A4TRPV1CYP1A2KDM4E | |
| SCHEMBL27875769 | 0.83 | S100A4 (0.45) | PDK1S100A4TRPV1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112538073-A | Preparation method of pazopanib intermediate | 上海天慈中商药业有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-9832880-B2 | Electronic apparatus and method for manufacturing the same | Innolux Corporation (TW) | 2017-11-28 | — | — | US | disclosed |
| EP-2155645-B1 | HERBICIDALLY ACTIVE BICYCLIC 1,3-DIONE COMPOUNDS | SYNGENTA LTD (GB) | 2017-06-14 | — | — | EP | disclosed |
| EP-2155645-B1 | HERBICIDALLY ACTIVE BICYCLIC 1,3-DIONE COMPOUNDS | SYNGENTA LTD (GB) | 2017-06-14 | — | — | EP | disclosed |
| EP-2173755-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| EP-2173755-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| CN-104169277-B | Aurora kinase and flt3 kinase modulators | 赛勒姆公司 | 2016-10-12 | — | — | CN | disclosed |
| US-20160145248-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2016-05-26 | — | — | US | disclosed |
| EP-2812328-B1 | AURORA AND FLT3 KINASES MODULATORS | SAREUM LTD (GB) | 2015-11-18 | — | — | EP | disclosed |
| US-9133180-B2 | Aurora and FLT3 kinases modulators | SAREUM LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| EP-2102181-A1 | 4-PHENYL-PYRANE-3,5-DIONES, 4-PHENYL-THIOPYRANE-3,5-DIONES AND CYCLOHEXANETRIONES AS NOVEL HERBICIDES | Syngeta Participations AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009019015-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009019015-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008145336-A1 | HERBICIDALLY ACTIVE BICYCLIC 1,3-DIONE COMPOUNDS | SYNGENTA LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008145336-A1 | HERBICIDALLY ACTIVE BICYCLIC 1,3-DIONE COMPOUNDS | SYNGENTA LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008110307-A1 | 2-ARYL-5-HETEROCYCLYL-CYCLOHEXANE-1,3-DIONE COMPOUNDS AND THEIR USE AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110308-A2 | NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008071405-A1 | 4-PHENYL-PYRANE-3,5-DIONES, 4-PHENYL-THIOPYRANE-3,5-DIONES AND CYCLOHEXANETRIONES AS NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071405-A1 | 4-PHENYL-PYRANE-3,5-DIONES, 4-PHENYL-THIOPYRANE-3,5-DIONES AND CYCLOHEXANETRIONES AS NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | PDK1 830/4885S100A4 908/4885TRPV1 2551/4885 |
| US-20160145248-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | PDK1 3297/4885S100A4 2287/4885TRPV1 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.